FDA Rejects Benefit of Vadudastat for Anemia due to Chronic Kidney Disease

Article

The agency cited an increased risk of thromboembolic events driven by vascular access thrombosis in dialysis patients and increased risk of drug-induced liver injuries.

FDA Rejects Benefit of  Vadudastat for Anemia due to Chronic Kidney Disease

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for vadadustat, a potential treatment for anemia due to chronic kidney disease (CKD).

The CRL, issued to Akebia Therapeutics, is based on data the FDA said does not support a favorable benefit-risk assessment of the treatment for dialysis and non-dialysis patients with safety concerns over the failure to meet non-inferiority in MACE in the non-dialysis patient population.

There was also an increased risk of thromboembolic events driven by vascular access thrombosis in dialysis patients and an increased risk of drug-induced liver injuries.

The company is able to rectify some of the concerns outlined in the letter through new clinical trials.

"We are extremely disappointed to receive a CRL for vadadustat, a therapy that has the potential to help patients with anemia due to CKD. We continue to believe the data are supportive of a positive benefit-risk assessment of vadadustat for patients with anemia due to CKD, particularly in dialysis patients," said John P. Butler, Chief Executive Officer of Akebia, in a statement. "Despite this setback, we continue to work toward our purpose to better the lives of people impacted by kidney disease."

Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor aimed at mimicking the physiologic effect of altitude on oxygen availability.

Related Videos
Kaitlin Mayne, MBChB | Credit X.com
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
Fadi Fakhouri, MD, PhD | Credit: University of Lausanne
Helen Colhoun, MD | Credit: University of Edinburgh
Digital illustration of kidneys | Credit: Fotolia
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
© 2024 MJH Life Sciences

All rights reserved.